Transl Lung Cancer Res: Efficacy of second-line docetaxel + ramucirumab in patients with metastatic NSCLC without driver mutation

Chemotherapy combined with immune checkpoint inhibitor (CTx+ICI) therapy has become the first-line treatment of choice for patients with metastatic NSCLC without driver mutation
.

However, the optimal subsequent second-line therapy has not been determined

Chemotherapy combined with immune checkpoint inhibitor (CTx+ICI) therapy has become the first-line treatment of choice for patients with metastatic NSCLC without driver mutation

The study included 77 patients with a median age of 63 years (range 41-83 years), and 68.
8% were male
.

More than half of the patients had an ECOG-PS of 1 (54.

The study included 77 patients with a median age of 63 years (range 41-83 years), and 68.

All patients received platinum-based combined CTx+ICI as palliative first-line therapy, of which 83.

The ORR and DCR of second-line D+R therapy were 32.
5% and 62.
4%, respectively
.

The median progression-free survival with second-line therapy was 3.

The ORR and DCR of second-line D+R therapy were 32.

The median OS for initiation of second-line therapy was 7.
5 months (95% CI, 5.
1 10.
0)
.

Median OS from first-line therapy was 15.

The median OS for initiation of second-line therapy was 7.

PD-L1 TPS and KRAS mutation status was prognostic in univariate analysis
.

Only KRAS wild type had positive independent prognostic value

PD-L1 TPS and KRAS mutation status was prognostic in univariate analysis

In conclusion, studies have shown that D+R is an effective and safe second-line therapy for advanced NSCLC patients after failure of first-line CTx+ICI, regardless of histological type
.
However, patients with KRAS mutations did not gain PFS benefit from D+R
.

In conclusion, studies have shown that D+R is an effective and safe second-line therapy for advanced NSCLC patients after failure of first-line CTx+ICI, regardless of histological type
.
However, patients with KRAS mutations did not gain PFS benefit from D+R
.
Studies have shown that D+R is an effective and safe second-line therapy for patients with advanced NSCLC after failure of first-line CTx+ICI, regardless of histological type
.
However, patients with KRAS mutations did not gain PFS benefit from D+R
.
Studies have shown that D+R is an effective and safe second-line therapy for patients with advanced NSCLC after failure of first-line CTx+ICI, regardless of histological type
.
However, patients with KRAS mutations did not gain PFS benefit from D+R
.

 

Original source:

Original source:

Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E.
Efficacy of docetaxel plus ramucirumab as palliative second -line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
Transl Lung Cancer Res 2021;10(7):3093-3105.
doi: 10.
21037 /tlcr-21-197

Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E.
Efficacy of docetaxel plus ramucirumab as palliative second -line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
Transl Lung Cancer Res 2021;10(7):3093-3105.
doi: 10.
21037 /tlcr-21-197 leave a message here